Citadel Advisors’s Cardiol Therapeutics CRDL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRDL
MI
Citadel Advisors's CRDL Position: Q3 2026 in Review
Citadel Advisors reduced its Cardiol Therapeutics (CRDL) stake by 39% in Q3 2026, selling an estimated $494K and leaving 486,246 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #9033.
Citadel Advisors first reported a position in CRDL in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.11M in Q1 2026. 59 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.
- Citadel Advisors held 486,246 shares of Cardiol Therapeutics worth $807K as of Q3 2026.
- Citadel Advisors sold 310,283 Cardiol Therapeutics shares in Q3 2026, an estimated $494K.
- Cardiol Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #9033 holding.
- Citadel Advisors first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 14 quarters since.
- Citadel Advisors's Cardiol Therapeutics position peaked at $1.11M in Q1 2026.
- 59 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.